Argenx to Buy Forte Biosciences for $2.2 Billion to Expand Immunology Pipeline

3-line summary

• Belgian pharmaceutical company Argenx has agreed to acquire Forte Biosciences for $2.2 billion, according to the report.
• The acquisition is aimed at expanding Argenx's immunology pipeline, per the report.

This summary is our own processing of the source article; see the source link below for full context.